Multiple myeloma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 3
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• TIGIT 0
• AMPK 0
• B7-H3 0
• NRAS 1
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

3 of 3+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R01

  Modulation of Bone Formation and Fracture Repair During Cancer Development

  Washington University· Saint Louis, United States· US$577,398 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R50

  Curing Through Cooperation: Aligning Cooperative Groups to Investigate Novel Therapeutic Approaches to Cure Plasma Cell Dyscrasias

  Utah State Higher Education System--University of Utah· Salt Lake City, United States· US$173,767 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R44

  Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma

  Cellsbin, Inc.· Branford, United States· US$1,045,925 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · U01

  Comparative Modeling of Multiple Myeloma Prevention, Early Detection and Treatment Interventions

  Washington University· Saint Louis, United States· US$848,978 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Overcoming CAR T cell resistance by tumor-restricted IL-12 driven anti-tumor immunity

  University of California Los Angeles· Los Angeles, United States· US$477,666 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Germany· EU contribution €1,466,571· until Oct 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spain· EU contribution €9,998,178· until Sept 2031· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Germany· EU contribution €9,999,253· until May 2028· 8 countries

10 of 332 running projects, newest first. Listed amounts together: US$252.1m + €35.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• AI-based automated body composition analysis from whole-body MRI and (PET-) CT: an intermodal comparison from same-day examinations.

  Cancer Imaging, Oct 2026

• AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.

  Blood Adv, Sept 2026

• Encephalopathy Post CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Beyond ICANS.

  J Investig Med High Impact Case Rep, Aug 2026

• [Imaging in monoclonal plasma cell disorders : Multiple myeloma, smouldering multiple myeloma and MGUS].

  Radiologie (Heidelb), Jul 2026

• [Differential diagnoses of malignant bone marrow diseases].

  Radiologie (Heidelb), Jul 2026

• Relapsing CNS involvement in MGUS-an Occam's razor?

  BMJ Case Rep, Jul 2026

• Non-secretory Multiple Myeloma: A Challenge to Diagnose.

  Mymensingh Med J, Jul 2026

• Quantitative assessment of tumor burden in multiple myeloma using MY-RADS from whole-body MRI: comparison with established prognostic biomarkers.

  Cancer Imaging, Jun 2026

• Beyond the borders-coma as a complication of imported Japanese encephalitis: a case report.

  J Med Case Rep, Jun 2026

• Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions.

  Eur Radiol Exp, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.